Value
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 7.0 |
| P/S | 8.9 |
| EV/EBITDA | 6.5 |
| Fwd P/E | 9.6 |
| PEG | 3.3 |
| Analyst target | 7.5 |
- ▸Forward P/E: 7.8x
- ▸PEG: 3.64
- ▸Attractively valued
SNY · Why this verdict
Why Sanofi (SNY) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Sanofi is a large pharmaceutical company with strong 16% operating margins, 221% free cash flow conversion, and 3 of 4 recent earnings beats, but faces a confirmed death cross with falling on-balance volume and a dividend payout ratio of 552% that appears structurally unsustainable.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Sanofi earns 16% operating margins and converts 221% of net income to free cash flow — meaning the company generates more than twice its reported profits in actual cash, reflecting a capital-light pharmaceutical business model with strong recurring royalty and product cash flows. Quality breakdown | Free cash flow conversion remains above 150% of net income for at least 3 of the next 4 reported periods. | →Stable |
| CounterA 221% FCF-to-income ratio can reflect non-cash charges (depreciation, amortization of acquired intangibles) that inflate stated conversion; the underlying cash generation may be more modest than it appears. | ||
Sanofi has beaten analyst earnings estimates in 3 of the last 4 quarters with an average positive surprise of 3.4%, demonstrating consistent execution across a large and diversified pharmaceutical portfolio. Earnings | The company delivers at least 2 more earnings beats over the next 4 quarters, maintaining positive average surprises above 2%. | →Stable |
| CounterA growth score of 2.0 out of 10 reflects weak underlying expansion momentum, and the single miss of -9% in July 2025 suggests the company is vulnerable to therapeutic area-specific setbacks. | ||
The stock has triggered a confirmed death cross with a 200-day moving average slope of -1.1% over 30 days, falling on-balance volume, and an RSI of 48 — signaling a technically negative intermediate-term trend despite improving MACD. Momentum breakdown | Price must recover above the 200-day moving average and sustain that level for at least 30 consecutive days for the downtrend thesis to be invalidated. | →Stable |
| CounterMACD is improving and RSI is at 48 (neutral), and the recovery pattern setup suggests selling pressure may be exhausting — MACD can often inflect ahead of price recovery in pharmaceutical stocks. | ||
Sanofi's dividend payout ratio of 552% of earnings — though the high FCF conversion may partially offset this — is flagged as a yield trap where the headline dividend yield may not be sustainably covered by reported net income, creating risk of a dividend reduction. Catalyst breakdown | Dividend payout ratio as a percentage of free cash flow remains below 100% over the next 12 months, confirming the dividend is covered by actual cash generation. | →Stable |
| CounterGiven the 221% FCF-to-net-income ratio, the 552% payout ratio relative to net income may be misleading — on a cash basis the dividend may be well-covered, and large pharmaceutical companies rarely cut dividends without a major earnings collapse. | ||
Sanofi earns 16% operating margins and converts 221% of net income to free cash flow — meaning the company generates more than twice its reported profits in actual cash, reflecting a capital-light pharmaceutical business model with strong recurring royalty and product cash flows.
→StableQuality breakdown
- Expectation
- Free cash flow conversion remains above 150% of net income for at least 3 of the next 4 reported periods.
CounterA 221% FCF-to-income ratio can reflect non-cash charges (depreciation, amortization of acquired intangibles) that inflate stated conversion; the underlying cash generation may be more modest than it appears.
Sanofi has beaten analyst earnings estimates in 3 of the last 4 quarters with an average positive surprise of 3.4%, demonstrating consistent execution across a large and diversified pharmaceutical portfolio.
→StableEarnings
- Expectation
- The company delivers at least 2 more earnings beats over the next 4 quarters, maintaining positive average surprises above 2%.
CounterA growth score of 2.0 out of 10 reflects weak underlying expansion momentum, and the single miss of -9% in July 2025 suggests the company is vulnerable to therapeutic area-specific setbacks.
The stock has triggered a confirmed death cross with a 200-day moving average slope of -1.1% over 30 days, falling on-balance volume, and an RSI of 48 — signaling a technically negative intermediate-term trend despite improving MACD.
→StableMomentum breakdown
- Expectation
- Price must recover above the 200-day moving average and sustain that level for at least 30 consecutive days for the downtrend thesis to be invalidated.
CounterMACD is improving and RSI is at 48 (neutral), and the recovery pattern setup suggests selling pressure may be exhausting — MACD can often inflect ahead of price recovery in pharmaceutical stocks.
Sanofi's dividend payout ratio of 552% of earnings — though the high FCF conversion may partially offset this — is flagged as a yield trap where the headline dividend yield may not be sustainably covered by reported net income, creating risk of a dividend reduction.
→StableCatalyst breakdown
- Expectation
- Dividend payout ratio as a percentage of free cash flow remains below 100% over the next 12 months, confirming the dividend is covered by actual cash generation.
CounterGiven the 221% FCF-to-net-income ratio, the 552% payout ratio relative to net income may be misleading — on a cash basis the dividend may be well-covered, and large pharmaceutical companies rarely cut dividends without a major earnings collapse.
Per-dimension breakdown
Quality
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 2.2 |
| ROA | 3.1 |
| Gross margin | 10.0 |
| Op margin | 8.0 |
| Net margin | 8.0 |
| Current ratio | 4.0 |
| FCF quality | 10.0 |
| Moat | 7.2 |
| Rule of 40 | 7.2 |
| Piotroski F | 7.8 |
- ▸Strong margins: 16%
- ▸Excellent cash conversion: 221% FCF/NI
- ▸Rule of 40: 41 (pass)
- ▸Strong Piotroski F-Score: 7/9
Growth
2.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 4.0 |
| EPS growth | 0.0 |
Momentum
1.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 0.0 |
| OBV | 1.0 |
| MA position | 1.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -1.1%/30d — confirmed downtrend
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 8.2 |
| Analyst rating | 6.9 |
| Price target | 8.8 |
- ▸LLM news sentiment: +0.65 (n=5)
- ▸Light analyst coverage (9.0) — signal dampened
- ▸Analyst upside: 34%
Insider
5.0/10data confidence 50%Peer rank
5.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.6 |
| quality rank | 2.5 |
| growth rank | 6.3 |
Technical
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 8.2 |
| support resistance | 7.9 |
| 52w position | 6.4 |
Risk (lower is worse)
7.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 9.8 |
| days to cover | 8.2 |
| volatility | 6.9 |
| put call | 10.0 |
| implied vol | 7.3 |
| max pain risk | 3.0 |
| beta | 10.0 |
| debt equity | 8.9 |
| news risk | 5.0 |
- ▸Above max pain $30
Catalyst
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 4.2 |
| dividend safety | 5.2 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
- ▸Dividend: 585.0%
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (6)
- ASYMMETRY:3.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:1.1<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (0)
none
Reward-to-Risk
3.27
Upside
+16.3%
Downside
5.0%
Sizing output
AVOID
SetupFALLING_KNIFE — Death cross, below all MAs, RSI 35, MACD bearish
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 7.9) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:1.1<4.5, DEATH_CROSS:HARD_BLOCK) reinforce the read. Current asymmetry R:R is 3.27 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 7.9, Risk (lower is worse) at 7.7, and Technical at 7.5; the weakest are Momentum at 1.1, Growth at 2.0, and Insider at 5.0. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 3.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Sanofi earns 16% operating margins and converts 221% of net income to free cash flow — meaning the company generates more than twice its reported profits in actual cash, reflecting a capital-light pharmaceutical business model with strong recurring royalty and product cash flows.
Trip ifFree cash flow conversion falls below 100% of net income for 2 consecutive quarters, signaling the cash quality advantage is eroding.
- P2Sanofi has beaten analyst earnings estimates in 3 of the last 4 quarters with an average positive surprise of 3.4%, demonstrating consistent execution across a large and diversified pharmaceutical portfolio.
Trip ifEPS surprise falls below 0% in at least 2 of the next 4 quarters, indicating the execution consistency is breaking down.
- P3The stock has triggered a confirmed death cross with a 200-day moving average slope of -1.1% over 30 days, falling on-balance volume, and an RSI of 48 — signaling a technically negative intermediate-term trend despite improving MACD.
Trip ifPrice drops below $40.00, more than 8% below the current $43.80, confirming the downtrend has accelerated rather than stabilized.
- P4Sanofi's dividend payout ratio of 552% of earnings — though the high FCF conversion may partially offset this — is flagged as a yield trap where the headline dividend yield may not be sustainably covered by reported net income, creating risk of a dividend reduction.
Trip ifThe company announces a dividend cut of more than 20% from current levels, or earnings coverage of the dividend falls below 50% on a trailing twelve-month basis.